DNAJC13: A Potential Drug Target and Biomarker (G23317)

Target Name: DNAJC13

NCBI ID: G23317

DNAJC13

DNAJC13: A Potential Drug Target and Biomarker

Introduction

DNAJC13, a member of the DNAJC13 gene family, is a non-coding protein that plays a crucial role in various cellular processes. DNAJC13 is expressed in most tissues and cells and is involved in various cellular processes, including DNA replication, transcription, and repair . It is also known to be a protein that can interact with numerous drug targets, making it an attractive drug target for researchers to explore. In this article, we will explore the potential drug target and biomarker properties of DNAJC13.

Potential Drug Target

DNAJC13 has been shown to interact with numerous drug targets, including histones, RNA-binding proteins, DNA-binding proteins, etc. The interaction between these drug targets and DNAJC13 can lead to conformational changes in DNAJC13, thereby affecting biological processes such as DNA replication and transcription. These interactions also indicate that DNAJC13 has important implications in drug research.

The possibility of DNAJC13 as a drug target mainly comes from the protein domain it contains. These domains include DnaJ, DnaJ-like, RNA-binding domains, etc. DNAJ is the core domain of DNAJC13 and is a protein composed of 110 amino acids. The function of DNAJ is to regulate the stability of histones by binding to histones, thereby affecting DNA replication and transcription.

The DNAJ-like domain is a minor domain of DNAJC13 and is also a domain composed of amino acids. It binds to DNA-binding proteins, which can bind to amino acids in the DNAJ-like domain, thereby enhancing the interaction between the DNAJ-like domain and DNA-binding proteins.

The RNA-binding domain is another domain of DNAJC13 and is also a domain composed of amino acids. The RNA-binding domain can bind RNA molecules, thereby promoting the interaction between RNA-binding proteins and DNAJC13, further affecting the biological processes of DNA.

Biomarker

DNAJC13 has broad application prospects in disease diagnosis and treatment. It is expressed in many tumor cells and is closely related to the growth, invasion and metastasis of tumor cells. Therefore, DNAJC13 can be used as a potential biomarker for tumors.

The expression level of DNAJC13 can also be used as a monitoring indicator of the therapeutic effect of certain diseases. For example, the expression level of DNAJC13 can be used as a monitoring indicator of the effectiveness of treating a certain cancer. By detecting the expression level of DNAJC13, the therapeutic effect of drugs on tumors can be evaluated and provide important treatment reference for clinicians.

Conclusion

DNAJC13 is a protein with broad application prospects in drug research and tumor diagnosis. Its expression level can be used as a monitoring indicator of drug effectiveness and as an important biomarker for tumor diagnosis and treatment. Therefore, studying the structure and function of DNAJC13 drug targets is of great significance for the development of new drugs and tumor diagnostic methods.

Protein Name: DnaJ Heat Shock Protein Family (Hsp40) Member C13

Functions: Involved in membrane trafficking through early endosomes, such as the early endosome to recycling endosome transport implicated in the recycling of transferrin and the early endosome to late endosome transport implicated in degradation of EGF and EGFR (PubMed:18256511, PubMed:18307993). Involved in the regulation of endosomal membrane tubulation and regulates th dynamics of SNX1 on the endosomal membrane; via association with WASHC2 may link the WASH complex to the retromer SNX-BAR subcomplex (PubMed:24643499)

The "DNAJC13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAJC13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets